| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8651042 | American Heart Journal | 2018 | 9 Pages |
Abstract
In summary, although XO inhibition with febuxostat was well tolerated and lowered serum urate, it did not improve the primary end point of the study, CEF measured using MRI after 6 weeks of treatment. In conclusion, these findings suggest that short-term inhibition of XO does not significantly improve impaired CEF in patients with stable CAD.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Allison G. MD, Micaela MD, Michael PhD, Shenghan MD, MPH, Matthew MD, Elayne RN, BSN, Robert N. MPH, Andrew MD, Robert G. MD, Gary MD,